Oxcarbazepine
| Evidence Level: L4 | Predicted Indications: 1 |
Table of Contents
Oxcarbazepine: Restless legs syndrome
One-Sentence Summary
Oxcarbazepine is an antiseizure medication originally used to treat partial (focal) epilepsy and partial motor epilepsy.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Restless legs syndrome |
| TxGNN Prediction Score | 0.9989 |
| Evidence Level | L4 |
| India Market Status | Listed in a compiled Indian medicine price dataset (at least 20) – CDSCO approval status is not included in this data |
| Number of Listed Products | at least 20 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the data compiled for this report. Based on known pharmacology, oxcarbazepine is a sodium channel blocker established for focal epilepsy, and its efficacy there is well documented. The retrieved literature describes its antiseizure activity in partial and secondarily generalized seizures, with the active 10-monohydroxy metabolite responsible for much of the clinical effect.
Visual (photosensitive or occipital) epilepsy is often focal in origin, so a mechanistic overlap with the approved indication is plausible. However, none of the retrieved publications addresses visual epilepsy specifically for oxcarbazepine. The link is therefore an extrapolation from the focal epilepsy indication, not direct evidence.
Other predicted indications show a similar pattern:
| Predicted indication | Score | Evidence level | Main support |
|---|---|---|---|
| Restless legs syndrome | 0.9989 | L4 | Two case reports (2006, 2009) and a narrative review mention |
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
No literature directly studies oxcarbazepine in visual epilepsy. The items below are the most relevant background publications retrieved for this prediction.
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 29898971 | 2018 | Guideline | Neurology | AAN/AES guideline update on new antiepileptic drugs for new-onset focal or generalized epilepsy |
| 35380580 | 2022 | Review | JAMA | Review of antiseizure medications for adults with epilepsy |
| 39899099 | 2025 | Review | Continuum | Update on antiseizure medications: pharmacokinetics, indications and modes of use |
| 33334546 | 2020 | Not classified | Seizure | Current role of carbamazepine and oxcarbazepine in epilepsy management |
| 11772334 | 2002 | Review | Expert Opin Pharmacother | Efficacy in partial-onset seizures, trigeminal neuralgia, and early signals in other conditions |
| 17560495 | 2007 | Not classified | Pediatr Neurol | Antiepileptic drugs and visual adverse effects (visual field and colour vision deficits) |
| 35431799 | 2022 | Review | Front Mol Neurosci | Phenotypic spectrum, treatment and prognosis of SCN2A-related epilepsy in 72 children |
| 11738014 | 2001 | Not classified | Neurologia | Oxcarbazepine derived from carbamazepine; efficacy in partial and secondarily generalized seizures; not indicated in myoclonic or absence epilepsies |
India Market Information
Oxcarbazepine is marketed in India as single-ingredient tablets, with 20 valid registrations and none cancelled. Approved indication text is not available for these registrations. Five main registrations are shown below.
| Authorization Number | Product Name | Dosage Form | Manufacturer |
|---|---|---|---|
| 168011 | Oxnig 600mg Tablet SR | Strip of 10 sustained-release tablets | Snig Pharmaceuticals Pvt Ltd |
| 233930 | Vinlep 450 Tablet | Strip of 10 tablets | Sanofi India Ltd |
| 27743 | Boxital 300mg Tablet | Strip of 10 tablets | Sanity Pharma |
| 50654 | Carbamac 600mg Tablet | Strip of 10 tablets | Macleods Pharmaceuticals Pvt Ltd |
| 163996 | Oxepin 600mg Tablet | Strip of 10 tablets | Icon Life Sciences |
Safety Considerations
- Contraindication-related conditions (from the knowledge graph, not label text): anxiety disorder, neurotic disorder, dysthymic disorder, impaired renal function, inappropriate ADH syndrome, nephrogenic syndrome of inappropriate antidiuresis.
- Drug Interactions: 248 known interactions. All 20 listed are of Moderate level, including hydrocortisone, dexamethasone, betamethasone, triamcinolone, cholecalciferol, calcitriol, pioglitazone, saxagliptin, linagliptin, omeprazole, clarithromycin, aprepitant, morphine, and dronabinol.
- Seizure aggravation: The literature reports oxcarbazepine-induced myoclonic status epilepticus in juvenile myoclonic epilepsy and notes that it can worsen some generalized epilepsies. This matters for reflex epilepsies that may be idiopathic generalized.
- Visual effects: A review notes that antiepileptic drugs can cause visual disturbances, which deserves attention in any visual-epilepsy use.
Package insert warnings and contraindications were not available; please refer to the package insert for full safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: Package insert safety data and mechanism data are also missing, so safety screening cannot proceed.
To proceed, the following is needed:
- Package insert warnings and contraindications from the India regulatory source (currently a blocking gap)
- Detailed mechanism of action data (e.g., from DrugBank)
- Targeted literature review or case series of oxcarbazepine in photosensitive or occipital epilepsy
- Clarification of whether visual epilepsy cases are focal (where oxcarbazepine fits) or generalized (where it may worsen seizures)
- A drug-interaction management plan given the 248 known interactions
Other candidates: Restless legs syndrome (L4, case reports only) is a research question rather than a development candidate. Status epilepticus is not advisable to advance because of the seizure-exacerbation safety signal and the lack of an acute-use formulation pathway. The remaining reflex seizure predictions (L5) should stay on Hold.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.